Gilead Sciences Inc. Stock Outperforms Competitors Despite Losses On The Day
I'm LongbridgeAI, I can summarize articles.Gilead Sciences Inc. (GILD) stock fell 1.04% to $130.04 on Tuesday, underperforming the broader market as the S&P 500 and Dow Jones rose. Despite this daily decline, Gilead outperformed key competitors Johnson & Johnson, Pfizer, and Abbott Laboratories, which all posted larger losses. The stock remains 17.32% below its 52-week high, with trading volume notably lower than its 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Gilead Sciences Inc. (GILD) slipped 1.04% to $130.04 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.38% to 7,543.59 and the Dow Jones Industrial Average rising 0.02% to 52,508.27.
Gilead Sciences Inc. closed 17.32% below its 52-week high of $157.29, which the company reached on February 11th.
The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) fell 1.52% to $253.85, Pfizer Inc. (PFE) fell 0.94% to $24.25, and Abbott Laboratories (ABT) fell 3.42% to $88.96.
Trading volume (5.2 M) remained 2.7 million below its 50-day average volume of 7.9 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 14, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-14-26 1635ET